A Comparative Analysis of Healthcare Supply Chain Models: Insights from the United Kingdom’s NHS and China’s Volume-Based Procurement System
DOI:
https://doi.org/10.54097/k1p0by42Keywords:
Health care procurement, supply chain management, National Health Service (NHS), National Volume-Based Procurement (NVBP), comparative analysis.Abstract
The healthcare procurement systems are crucial for achieving financial efficiency and clinical effectiveness in national health services. The paper includes a comparative evaluation of two major health care procurement systems: the procurement system of the United Kingdom based on the National Health Service (NHS), and the theoretically based system of procurement in China, which is the National Volume-Based Procurement (NVBP). The research includes a comprehensive literature review and policy analysis of their organizational structure, operation, cost-efficiencies, and governing mechanisms. The findings indicate that, on average, China has achieved relevant cost savings in pharmaceuticals and devices through centralized buying and competitive bidding. The NHS system, however, has been reporting good performance in terms of quality assurance, transparency, and involvement of stakeholders, whereby the governance is partially decentralized but coordinated. According to the comparative analysis, China’s adapted model excels in achieving high cost-containment on a large scale; however, the NHS’s adapted model prioritizes quality, accountability, and sustainability. Both systems provide curative lessons: NVBP focuses on the benefits of centralization and volume guarantees, and NHS focuses on the necessity to engage the clinics and make purchasing decisions on an evidence-based basis. The paper concludes that hybrid solutions, including cost-effectiveness, governance, and quality standards, may be the most suitable solutions in health care systems in the world. These lessons are included in the general discourse of global healthcare supply chain management and can be used to inform future policy-making in providing cheap, innovative, and quality services.
Downloads
References
[1] Parmar, D., Mathauer, I., Bloom, D., Dkhimi, F., Abuosi, A.A., Chen, D., Chukwuma, A., de Claro, V., Comsa, R., Domingo, A.F. and Doroshenko, O. Adjustments in purchasing arrangements to support the COVID-19 health sector response: evidence from eight middle-income countries. Health policy and planning, 2024, 39(2), pp.213-223.
[2] Sanderson, J., Lonsdale, C., Mannion, R. and Matharu, T. Towards a framework for enhancing procurement and supply chain management practice in the NHS: lessons for managers and clinicians from a synthesis of the theoretical and empirical literature. Health Services and Delivery Research, 2015, 3(18), pp.1-134.
[3] Hinrichs, S., Jahagirdar, D., Miani, C., Guerin, B. and Nolte, E. Learning for the NHS on procurement and supply chain management: a rapid evidence assessment. Health and Social Care Delivery Research, 2014, 2(55), pp.1-132.
[4] Sanchez-Graells, A. Centralisation of procurement and supply chain management in the English NHS: some governance and compliance challenges. N. Ir. Legal Q., 2019, 70, p.53.
[5] Chang, Q., Tian, Y., Gao, L. and Xia, N. Challenges and countermeasures for China's centralised volume‐based procurement policy in healthcare. The International Journal of Health Planning and Management, 2024, 39(5), pp.1330-1349.
[6] Zhu, Z., Wang, Q., Sun, Q., Lexchin, J. and Yang, L. Improving access to medicines and beyond: the national volume-based procurement policy in China. BMJ Global Health, 2023, 8(7), p.e011535.
[7] Chen, Y., Ji, X., Xiao, H., Unger, J.M., Cai, Y., Mao, Z. and Yeung, K. Impact of the pilot volume-based drug purchasing policy in China: Interrupted time-series analysis with controls. Frontiers in Pharmacology, 2021, 12, p.804237.
[8] Xing, Q., Tang, W., Li, M. and Li, S. Has the volume-based drug purchasing approach achieved equilibrium among various stakeholders? Evidence from China. International Journal of environmental research and public health, 2022, 19(7), p.4285.
[9] Li, X. and Xu, J. Does China’s national volume-based drug procurement policy promote or hinder pharmaceutical innovation?. Frontiers in Pharmacology, 2024, 15, p.1392239.
[10] Hu, Y., Chen, S., Qiu, F., Chen, P. and Chen, S. Will the volume-based procurement policy promote pharmaceutical firms’ R&D investment in China? An event study approach. International Journal of Environmental Research and Public Health, 2021, 18(22), p.12037.
[11] Geropoulos, N., Voultsos, P., Geropoulos, M., Tsolaki, F. and Tagarakis, G. Hybrid model: a promising type of public procurement in the healthcare sector of the European Union. Frontiers in Public Health, 2024, 12, p.1359155.
[12] Bowden, N., Figueroa, J.F. and Papanicolas, I. Bridging borders: Current trends and future directions in comparative health systems research. Health services research, 2024, 59(6), p.e14385.
[13] National Audit Office. NHS Supply Chain and efficiencies in procurement. NAO Report, 2024.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Highlights in Business, Economics and Management

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







